About the Conference:

Striving to maximize profitability, reimbursement professionals within diagnostic manufacturers and laboratories must contend with decreasing payment rates due to PAMA as well as increasing requirements for prior authorization and uncertainty regarding PLA code effectiveness. The Q1’s Diagnostic Coverage & Reimbursement Conferences offer industry leaders practical insight into strategies to develop test-specific frameworks and meet the growing need for clinical utility and product performance evidence. Reimbursement professionals will benefit from peer-to-peer sharing of tactics to clearly define end-points in diagnostic clinical trial design, methods to position real-world evidence for maximum impact to payers, and important private payer and government policy updates effecting payment for diagnostics.